leisure time -WSS

leisure time

author：entertainment 2025-09-02 08:22:38 - browse：3

Surrounded by tablets, an elder miniature figure walks with a cane next to a stethoscope — coverage from STAT — Adobe

Medicare Advantage is arguably the most controversial health care program right now — a sentiment that was bolstered Friday by striking new data about overpayments and an uncommon political jab during a routine meeting of policy wonks.

The Medicare Payment Advisory Commission, a group that advises Congress on Medicare policy, gathered to discuss its pending March report on the state of Medicare Advantage, the alternative to traditional Medicare that is run by health insurance companies. Medicare Advantage is expected to cost taxpayers $507 billion this year, according to the latest federal estimates.

The group, known as MedPAC, came to several familiar conclusions from the staff’s presentation and report: The federal government significantly overpays Medicare Advantage insurers because they attract healthier, lower-cost people into their plans and then excessively code those people’s health conditions — making Medicare Advantage a drain on taxpayers. MedPAC’s staffers also reiterated that Medicare Advantage’s quality rating system is “not a good basis for judging quality,” and therefore leads to further overpayments because insurers are paid bonuses based on this quality system.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Senate panel eyes new effort on drug shortages

WSS

Researchers explore possible ties between long Covid, menopause

Beam Therapeutics to lay off 20% of its staff, re

Why Charlie Gard's case is so disturbing to Americans

FDA gives detailed accounting of AI

UnitedHealth’s board chair also owns a personal investment firm

FDA authorizes Novavax’s updated Covid

Wikipedia

leisure time

explore

Medical leaders decry Supreme Court decision on affirmative action

When women are denied an abortion, their children fare worse than peers

The cancer drug shortage isn’t new — and neither are the solutions

Chemotherapy drug shortage eases slightly but still widespread

Moonlake's readout produced a cash windfall. Risks remain

AI can decode, harness the power of the humane immune system

Bright Health sells Medicare Advantage business to Molina

FDA rejects Alnylam's heart disease treatment over insufficient data

Hepatitis C has a cure — but many Americans still lack access to it

Solve the antibiotic resistance crisis with preventive drugs

focus

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Was Amgen transparent enough on FDA's concern on cancer drug?

When women are denied an abortion, their children fare worse than peers

NIH confirmation hearing shows politicization of research

2023 STAT Wunderkinds: get to know the winners

FDA gives detailed accounting of AI

hotspot

explore

explore

explore